Deutsche Bank’s Ernexa Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-2
Closed -$35K – 4178
2022
Q1
$35K Sell
2
-1
-33% -$19K ﹤0.01% 3940
2021
Q4
$79K Buy
3
+1
+50% +$54.4K ﹤0.01% 3798
2021
Q3
$168K Hold
2
– – ﹤0.01% 3655
2021
Q2
$273K Buy
+2
New +$288K ﹤0.01% 3603
2017
Q2
– Hold
0
– -$9K – 4988
2017
Q1
– Hold
0
– – – 4631

Other funds holding ERNA

Deutsche Bank's ERNA Position: Q2 2022 in Review

Deutsche Bank sold out of Ernexa Therapeutics (ERNA) in Q2 2022, closing a stake of 2 shares — an estimated $35K sold.

Deutsche Bank first reported a position in ERNA in Q2 2021 and held it in 4 quarters. The position peaked at $273K in Q2 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

  • Deutsche Bank reported no remaining Ernexa Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 2 Ernexa Therapeutics shares in Q2 2022, an estimated $35K.
  • Deutsche Bank first reported a position in Ernexa Therapeutics in Q2 2021 and held it in 4 quarters.
  • Deutsche Bank's Ernexa Therapeutics position peaked at $273K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Ernexa Therapeutics as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.